What Are the Key Trials in Younger Adults with Newly Diagnosed AML?

By Blood Cancer Talks - Last Updated: August 1, 2023

In this episode of “Blood Cancer Talks,” Eytan Stein, MD, of the Memorial Sloan Kettering Cancer Center, joins the hosts to outline key considerations for managing newly diagnosed acute myeloid leukemia (AML) in younger adults.

Dr. Stein discusses research on the impact of treatment delays, the RATIFY trial, maintenance therapy strategies, data on gemtuzumab ozogamicin, the latest treatment recommendations for AML, and more.

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Ayalew Tefferi, MD, on Career Development as a Clinician-Investigator

Angela Dispenzieri, MD, on Managing Newly Diagnosed AL Amyloidosis

ASH 2023 Myeloid Recap With Anand Patel, MD

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

What Are the Key Trials in Younger Adults with Newly Diagnosed AML?

Related